0001062993-26-001606
SEC filingMedicus Pharma Ltd. (MDCX), a clinical-stage biotech company, reported a net loss of $35.4M for FY 2025 ending December 31, 2025, driven by total operating expenses of $34.4M, including $17.9M in general and administrative, $7.7M in research and development, and $8.7M in in-process R&D for Teverelix. Loss from operations was $34.4M, with additional other expenses of $1.1M contributing to the net loss. Net loss attributable to common shareholders reached $47.3M after a $11.8M deemed dividend on warrant inducement, resulting in basic and diluted EPS of -$3 on 17.3M weighted average shares. Balance sheet shows $10.1M total assets, including $8.7M cash, against $10.0M liabilities, yielding minimal equity of $37K. Cash flows reflected $22.8M used in operations, $31.9M from financing, and $4.6M used in investing (Antev acquisition), netting a $4.5M cash increase to $8.7M. No revenue generated as a pre-commercial entity. Forward-looking, focus remains on Phase 2 trials for SkinJect (D-MNA for BCC) and Teverelix (GnRH antagonist), with ongoing financing via SEPA ($15M facility) and ATM ($15.3M) to fund development amid going concern risks.
Medicus Pharma Ltd. reported FY 2025 results with a $35.4M net loss, up from prior periods due to escalated R&D and G&A amid clinical advancements. Operating loss stood at $34.4M from $17.9M G&A, $7.7M R&D, and $8.7M IPR&D for Teverelix acquisition. Other expenses added $1.1M, including debenture fair value changes. Attributable loss to shareholders was $47.3M post $11.8M warrant dividend, with EPS at -$3 (17.3M shares). Total assets $10.1M (cash $8.7M), liabilities $10.0M, equity $37K. Cash increased $4.5M to $8.7M via $31.9M financing despite $22.8M ops burn.
No revenue reported; company is clinical-stage with focus on SkinJect Phase 2 (SKNJCT-003/004 for BCC) and Teverelix Phase 2b. Expenses tied to trials: R&D $7.7M, IPR&D $8.7M. No geographic or segment revenue breakdown as pre-commercial.
N/A - no revenue, pure loss-making ops. G&A dominated at 52% of opex; R&D/IPR&D 48%. No margins applicable.
Ops cash use $22.8M (net loss adjusted for $1.5M stock comp, $8.7M IPR&D). Financing $31.9M (shares/warrants $28.3M, debentures $11.9M net repayments). Investing -$4.6M (Antev). Liquidity: $8.7M cash vs. $9.9M current liabilities; working capital near zero. Debentures $5.2M current.
Ongoing Phase 2 readouts (SkinJect topline Q2 2026); Teverelix Phase 2b clearance. Financing via SEPA ($8.4M proceeds YTD), ATM, equity. Going concern doubt noted; needs funding for trials. Risks: trial failures, dilution, regulatory delays.